Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability
Frontiers in Oncology · 03.07.2026 · 16
DOI: 10.3389/fonc.2026.1768842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 03.07.2026. Verfasst von Xing Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
PARP inhibitors are standard maintenance therapies for ovarian cancer (OC), but evidence regarding how baseline physiological vulnerability relates to heterogeneity in comparative treatment effectiveness—beyond molecular biomarkers—remains limited. This study applied a causal inference framework, benchmarked against established molecular associations, to explore whether organ vulnerability is associated with variation in progression-free survival (PFS) between PARP inhibitors.
Methods
In this retrospective study of 604 OC patients, we constructed an interpretable 0–3 organ vulnerability score (OVS) using routine pre-treatment laboratory indicators reflecting physiological reserve. A benchmark analysis in 280 patients with complete BRCA status evaluated whether the framework could reproduce established prognostic associations under real-world conditions. G-computation–based counterfactual survival standardization and causal forest analyses were applied to the full cohort to explore OVS-associated treatment heterogeneity, with directional reproducibility assessed in an independent external cohort (n = 58).
Results
The estimated association between BRCA mutation status and PFS was directionally consistent with prior clinical evidence (HR = 0.685, 95% CI: 0.490–0.959; P = 0.028). In the full cohort, a significant treatment-by-OVS interaction was observed (interaction HR = 0.488, 95% CI: 0.293–0.813; P = 0.006). Among patients with low vulnerability (OVS 0–1, n = 479), olaparib was associated with a modest PFS advantage over niraparib (HR = 0.744, P = 0.030). In patients with high vulnerability (OVS 2–3, n = 125), the estimated relative benefit associated with olaparib was more pronounced (HR = 0.363, P < 0.001); however, these estimates are model-dependent and should not be interpreted as definitive comparisons. The directional heterogeneity pattern was qualitatively reproduced in the external cohort. Exploratory heterogeneity analysis further identified individual-level variation in estimated treatment response, including a subset with estimated relative benefit favoring niraparib.
Conclusions
This retrospective exploratory analysis suggests that baseline physiological vulnerability may be associated with heterogeneity in the relative effectiveness of PARP inhibitors. These findings are hypothesis-generating and lay the groundwork for prospective investigation into physiological vulnerability as a correlate of heterogeneous treatment response in real-world oncology populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
- Oncology Department of Xiangya Hospital, Central South University, Changsha, China.
- Department of Oncology of the Second Xiangya Hospital, Central South University, Changsha, China.
Zitieren
APA
Zhou, X., Xiong, X., Yang, Z., Cao, Z., & Ni, Q. (2026). Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1768842
Vancouver
Zhou X, Xiong X, Yang Z, Cao Z, Ni Q. Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1768842
BibTeX
@article{Zhou2026,
author = {Zhou, Xing and Xiong, Xi'an and Yang, Zhen and Cao, Zhongping and Ni, Qianxi},
title = {Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1768842}
}
EUVIMED